“Global spending on healthcare is projected to surpass USD 18 trillion by 2040”, says Visiongain

07 November 2019
Pharma

Visiongain has launched a new pharma report “Radiofrequency Ablation Devices Market Report 2020-2030” Prospects by Product (Capital Equipment, Disposable Equipment, Reusable Equipment), Application (Surgical Oncology, Cardiology & Cardiac Rhythm Management, Cosmetology, Gynecology, Pain Management) and Geography.

The global radiofrequency ablation (RFA) devices market is projected to grow on account of growing preference of minimally invasive procedures coupled with increasing prevalence of cardiovascular diseases. The global radiofrequency ablation devices market is projected to grow at a lucrative CAGR of ~11% from 2020 to 2030 and is anticipated to surpass USD 3 billion by 2020.

Radiofrequency ablation devices market growth is favored by growing cardiovascular disease prevalence, such as atrial fibrillation, growing cancer incidence cases, and increasing demand for minimally invasive procedures. The demand, however, is constrained by the high cost of treatment, poor knowledge of the process, and availability of other treatment options. The effect of drivers is projected to be higher than the restraints. 

Growing healthcare expenditure and preference for minimally invasive surgery has become a major driver of market growth. Radiofrequency ablation is an effective therapy for small cancers and can be repeated for the occurrence of new cancer. According to the U.S. Census Bureau, global spending on healthcare is projected to surpass USD 18 trillion by 2040, at a CAGR of over 2%. This is projected to have a positive impact on the overall revenue generation from RFA devices.

Also, the market is anticipated to improve the increasing geriatric population coupled with raising life expectancy. Geriatric individuals are more vulnerable to chronic disease, increasing the need for highly effective care, which in turn stimulates the need for RF ablation. The world's population aged 60 and above is expected to surpass 2 billion by 2050 as per the reports of the WHO.

However, factors such as high cost of treatment coupled with low knowledge of advanced treatment availability have a negative impact on the global demand for radiofrequency ablation devices. Also, it is projected that increased spending capacity on healthcare globally and particularly in Asia Pacific's developing countries will be witnessing the most lucrative growth opportunities for the manufacturers over the forecast period. Also, the emergence of innovative developments in radiofrequency ablation devices, which work effectively for minimally invasive surgical procedures, is anticipated to propel market growth further.

Due to the increased risk of developing atrial fibrillation (AF), the cardiology and cardiac rhythm control segment is expected to grow at the highest CAGR during the forecast period. According to the National Service Framework for Coronary Heart Disease, the Department of Health, AF is the most popular method of arrhythmia and catheter ablation is projected to be one of the most commonly performed electrophysiological procedures over the forecast period, thus contributing to market growth.

It is anticipated that North America will remain dominant over the forecast period. The high prevalence of cancer, technological advances, high purchasing power and government support for quality health care are key factors leading to regional development.

Over the forecast period, Asia Pacific is predicted to experience the fastest CAGR. It is anticipated that the introduction of advanced technology such as multi-needle electrode displaying precision, portability, and cost-effectiveness will have a positive impact on the regional market. Increasing disposable income, developing healthcare services, and rapidly growing economic conditions in China and India's emerging markets are also responsible for boosting growth in Asia Pacific region.

Some of the major players operating in this industry are ANGIODYNAMICS, Arthrex, Inc., AtriCure, Inc., Baylis Medical, Bramsys Indstria e Comrcio Ltda, BOSTON SCIENTIFIC CORPORATION, COSMAN MEDICAL, INC., ENDO-FLEX GmbH, Epimed International, Halyard Health, Inc., Hologic, Inc., Inomed Medizintechnik GmbH, JOHNSON & JOHNSON (J&J) SERVICES, LLC, MEDTRONIC, R. Bard, Inc., Sfm medical devices GmbH, SMITH & NEPHEW, ST. JUDE MEDICAL, STRYKER, Sutter Medizintechnik GmbH among other prominent players.

Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongain.com or call her on +44 (0) 207 336 6100.

About Visiongain
Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.

Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.

Recent News

Visiongain Publishes Healthcare Cold Chain Logistics Market Report 2020-2030

. The growth of this market is majorly driven by increasing sales of temperature sensitive pharmaceutical products, longer life expectancy and rising geriatric population are some of the prominent factors.

16 September 2020

Read

Visiongain Publishes Vaccines Sales Market Report 2020-2030

Visiongain forecasts a continuing growth in global market, submarket and product sales as human vaccines drive pharmaceutical business sales. New key players and technological progress will enter the industry, leading to an increase in the market size of the world market for human vaccines in general.

14 September 2020

Read

Visiongain Publishes Ophthalmic Ultrasound Systems Market Report 2020-2030

The global ophthalmic ultrasound systems market is driven by factors such as the increasing prevalence of ocular disorders and diseases, adoption of novel ophthalmic technologies, rising focus on research & development, and growing health awareness amongst the population.

09 September 2020

Read

Visiongain Publishes Drug Discovery Outsourcing Market Report 2020-2030

The current COVID-19 pandemic is anticipated to have a minor impact on the overall outsourcing business outlook for global drug discovery. Also, significant growth during the COVID-19 pandemic is expected to be seen in the outsourcing of drugs and medicines needed to treat COVID-19 infections.

07 September 2020

Read

Kelloggs
3m
Thales
Shell
TEVA
Lockheed-Martin
Pfizer
Raytheon
Halliburton
Du-Pont
Honeywell
Daimler
BASF
Bayer
BP
BAE-Systems
Unilever